There are 2867 resources available
862P - Incidence of hypothyroidism following the use of various immune checkpoint inhibitor regimens in melanoma patients: Meta-analysis
Presenter: Vincas Urbonas
Session: Poster session 03
1704P - Multimodal approach to discover novel targets for antibody-drug conjugates by analyzing distinct expression patterns of frequent copy number aberration
Presenter: Jimin Moon
Session: Poster session 11
1135P - Adverse event (AE) burden of nivolumab-based immuno-oncology (IO) therapy with/without chemotherapy (chemo) for first-line (1L) advanced non-small cell lung cancer (aNSCLC)
Presenter: Lee Schwartzberg
Session: Poster session 15
863P - Elderly patients (pts) with advanced melanoma: Results from the prospective real-world study GEM1801
Presenter: Eva Muñoz Couselo
Session: Poster session 03
1705P - HER2 intratumoral genetic and non-genetic heterogeneity in metastatic colorectal cancer
Presenter: Kentaro Sawada
Session: Poster session 11
1136P - Relationship between caloric intakes and sensitivity to immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients: The ELY-2 study
Presenter: Manuela Tiako Meyo
Session: Poster session 15
864P - Prognostic impact of MARCO and OAS1 expression in metastatic melanoma patients treated with anti-PD1: A proteomics and transcriptomics retrospective analysis
Presenter: Domenico Mallardo
Session: Poster session 03
1706P - Artificial intelligence-powered tumor purity assessment from H&E whole slide images associates with variant allele frequency of somatic mutations across 23 cancer types in TCGA cohorts
Presenter: Seokhwi Kim
Session: Poster session 11
1138P - Alternate pembrolizumab dosing interval in advanced NSCLC with PD-L1 >/= 50%: 3 weekly compared to 6 weekly dosing
Presenter: Lauren Jones
Session: Poster session 15
865P - TNFRSF1B gene variants on susceptibility, clinicopathological aspects, and prognosis of patients with cutaneous melanoma
Presenter: Carmen Passos Lima
Session: Poster session 03